Latest Kaiser Health News Stories
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss a flurry of proposals from the Trump administration on prices Medicare pays for drugs and the Affordable Care Act.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Stephanie Armour of The Wall Street Journal and Joanne Kenen of Politico discuss how protections for people with preexisting conditions have become a top issue in the elections, Trump administration efforts to make prescription drug prices more public and the start of Medicare’s annual open-enrollment period. Plus, Rovner interviews California Attorney General Xavier Becerra.
Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.
Drug pricing is a top issue in the run-up to the midterm elections.
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
Congress approved two bills last month that prohibit provisions keeping pharmacists from telling patients when they can save money by paying the cash price instead of the price negotiated by their insurance plan.
Addiction experts argue that buprenorphine, which drug users buy on the street, actually saves lives because it is used in place of more dangerous substances, like heroin and fentanyl.
Health insurers and pharmacy benefit managers are exploring how two legal provisions — which have been on the books for decades — could bring down the price tags of certain prescription medications.
In the bipartisan opioid bill headed to the president’s desk, hospice workers would be allowed to destroy patients’ unneeded opioids, reducing the risk that families misuse them.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
A project that started in a Boston Veterans Affairs facility will soon go nationwide. It puts naloxone, also known as Narcan, into emergency supplies cabinets throughout the VA system.
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
The protection is a win for people who get their needed, legitimate drugs from overseas.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Despite the growing epidemic of Americans misusing opioids and overdosing on the job, many employers turn a blind eye to addiction within their workforce — ill-equipped or unwilling to confront an issue they are at a loss to handle.
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren’t proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.